While rare diseases individually affect very few patients, the collective impact is staggering. Globally, the list of rare diseases has grown to approximately 7,000, and 350 million people are living with a rare disease. These diseases are serious, often life-threatening, and approximately half of those affected are children. The lack of available treatments leave patients and their families searching for new options and new hope.
In this webinar, QuintilesIMS experts Dr. Cynthia Jackson and Sheetal Telang address current industry challenges of rare and ultra-rare disease drug development and why developing seamless, efficient global operational solutions designed with the patient at heart is critical to help accelerate development of new treatments.
You will learn:
Cynthia Jackson, D.O., FAAP
Vice President and Head, Pediatric and Rare Disease Centers of Excellence
Therapeutic Strategy Director, Immunology and Internal Medicine, Therapeutic Science & Strategy Unit